Gilead Sciences’ (GILD) Buy Rating Reiterated at Jefferies Group LLC
Jefferies Group LLC restated their buy rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a research note issued to investors on Tuesday morning. They currently have a $83.00 price objective on the biopharmaceutical company’s stock.
A number of other analysts have also recently weighed in on GILD. Maxim Group reaffirmed a hold rating on shares of Gilead Sciences in a research report on Sunday, November 6th. Cowen and Company set a $120.00 price target on shares of Gilead Sciences and gave the stock a buy rating in a research report on Sunday, October 23rd. Piper Jaffray Companies reaffirmed a hold rating and set a $95.00 price target (down from $102.00) on shares of Gilead Sciences in a research report on Wednesday, February 8th. Zacks Investment Research cut shares of Gilead Sciences from a hold rating to a sell rating in a research report on Monday. Finally, Robert W. Baird reaffirmed an outperform rating and set a $100.00 price target on shares of Gilead Sciences in a research report on Wednesday, December 21st. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $87.20.
Shares of Gilead Sciences (NASDAQ:GILD) opened at 70.31 on Tuesday. The stock’s 50 day moving average price is $71.76 and its 200-day moving average price is $75.36. The firm has a market cap of $92.11 billion, a PE ratio of 7.07 and a beta of 1.11. Gilead Sciences has a 52-week low of $65.38 and a 52-week high of $103.10.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 7th. The biopharmaceutical company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.61 by $0.09. The business earned $7.30 billion during the quarter, compared to the consensus estimate of $7.16 billion. Gilead Sciences had a return on equity of 92.36% and a net margin of 44.43%. The business’s revenue for the quarter was down 13.9% on a year-over-year basis. During the same period in the prior year, the firm posted $3.32 EPS. On average, equities research analysts anticipate that Gilead Sciences will post $8.57 earnings per share for the current fiscal year.
This report was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this report can be accessed at http://www.dailypolitical.com/2017/02/17/gilead-sciences-gild-buy-rating-reiterated-at-jefferies-group-llc.html.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 30th. Stockholders of record on Thursday, March 16th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Tuesday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.47. This represents a $2.08 annualized dividend and a dividend yield of 2.96%. Gilead Sciences’s dividend payout ratio (DPR) is 18.91%.
In other news, insider John C. Martin sold 73,337 shares of the stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $73.59, for a total value of $5,396,869.83. Following the completion of the transaction, the insider now directly owns 3,204,433 shares in the company, valued at $235,814,224.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.40% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Thrivent Financial for Lutherans boosted its position in Gilead Sciences by 2.5% in the fourth quarter. Thrivent Financial for Lutherans now owns 2,263,089 shares of the biopharmaceutical company’s stock valued at $162,061,000 after buying an additional 56,110 shares during the period. IFM Investors Pty Ltd bought a new position in Gilead Sciences during the fourth quarter valued at about $1,213,000. Wall Street Access Asset Management LLC boosted its position in Gilead Sciences by 2.9% in the fourth quarter. Wall Street Access Asset Management LLC now owns 3,765 shares of the biopharmaceutical company’s stock valued at $270,000 after buying an additional 107 shares during the period. LeJeune Puetz Investment Counsel LLC bought a new position in Gilead Sciences during the fourth quarter valued at about $1,068,000. Finally, Independent Advisor Alliance bought a new position in Gilead Sciences during the fourth quarter valued at about $1,635,000. Institutional investors and hedge funds own 74.19% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.